×

Before you go!

Sign up for the FREE weekly email newsletter from the publishers of American Nurse Today. You’ll get breaking news features, exclusive investigative stories, and more — delivered to your inbox.

Sign up today!

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Drugs and Devices

On Oct. 5, the U.S. Food and Drug Administration (FDA) approved expansion of the use of Gardasil 9 (Human Papillomavirus (HPV) 9-valent Vaccine, Recombinant) to include women and men aged 27 through 45 years.

Read more via U.S. Food & Drug Administration . . .

Consuming one to two drinks four or more times per week, which is deemed healthy by current guidelines, increases the risk of premature death by 20%, compared with drinking three times a week or less, according to a study in Alcoholism: Clinical & Experimental Research.

Read more via Washington University . . .

On August 10, U.S. Food and Drug Administration (FDA) approved Annovera (segesterone acetate and ethinyl estradiol vaginal system), which is a combined hormonal contraceptive for women and is the first vaginal ring contraceptive that can be used for an entire year.

Read more via U.S. Food & Drug . . .

On August 8, the U.S. Food and Drug Administration (FDA) approved Poteligeo (mogamulizumab-kpkc) injection for IV use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. These are two rare, hard-to . . .

On July 30, the U.S. Food and Drug Administration (FDA) approved Azedra (iobenguane I 131) injection for intravenous use for the treatment of adults and adolescents age 12 and older with rare tumors of the adrenal gland (pheochromocytoma or paraganglioma) that are unresectable, have metastasized, and require systemic anticancer . . .

On July 18, the U.S. Food and Drug Administration (FDA) approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine . . .

Insurance denial rates for direct-acting antiviral drugs used to treat hepatitis C are high—more than 50% for those with private insurance—according to a study in Open Forum Infectious Diseases. The drugs have been a game-changer in saving patients lives.

Read more via Penn Medicine News and . . .

On June 4, the U.S. Food and Drug Administration (FDA) approved Fulphila (pegfilgrastim-jmdb) as the first biosimilar to Neulasta (pegfilgrastim) to decrease the chance of infection as suggested by febrile neutropenia in patients with non-myeloid cancer who are receiving myelosuppressive chemotherapy that has a clinically significant incidence . . .

People with a family history of alcohol use disorder (AUD) release more dopamine in the brain’s main reward center in response to the expectation of alcohol than people diagnosed with the disorder, or healthy people without any family history of AUD, according to a study in Biological Psychiatry: Cognitive . . .

On May 11, the U.S. Food and Drug Administration (FDA) approved Gilenya (fingolimod) to treat relapsing multiple sclerosis (MS) in children and adolescents age 10 years and older. This is the first drug FDA has approved for treating MS in pediatric patients.

Read more via FDA.gov . . .


Test Your Nursing Knowledge

Answer this interactive quiz to be entered to win a gift card.

  • This field is for validation purposes and should be left unchanged.

Insights Blog

Today’s News in Nursing

Advertisement